At that scale, Kraig Labs believes spider silk will move from a breakthrough biomaterial to a widely available, high-performance industrial fiber. A material that has no equal; lightweight, ...
We are delighted to announce dosing of the first subject in our Phase 1 study of TNV262, an important milestone for Tenvie and our mission to transform the treatment of neurological and peripheral ...
Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced positive topline results ...
SkinJect™, a novel localized immuno-oncology precision product focused on non-melanoma skin diseases, especially basal cell carcinoma (BCC) and Gorlin Syndrome, a rare autosomal dominant disease also ...
Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, manufacturing, and sale of products ...
In connection with the hiring of an employee, the Compensation Committee of Sagimet’s Board of Directors approved that an inducement grant of 9,600 stock options to purchase shares of the Company’s ...
Over 2 Million SOL Held with Approximately 95% Staked at ~7% Gross Annualized Yield; Total Assets of $269.1 Million, Up from $7.3 Million at Year-End 2024; Expanded Solana Ecosyst ...
About Neumora Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded to confront the greatest medical challenges of our generation by taking a fundamentally different ...
Company secures scalable multi-omics diagnostics platform and launches Mayo Clinic partnership adding to Lumee real-time biochemistry monitoring platform to advance pancreatic cancer applications ...
The presentation will be webcast live and can be accessed by visiting ‘Events & Presentations’, under ‘Events’, via the ‘Investors’ section of Immunocore’s website at www.immunocore.com. Following the ...
Dr. Boutain is a Board Certified Behavior Analyst at the doctoral level with extensive experience in early intervention, ABA program design, and clinical supervision. She has dedicated her career to ...
Strategic financing to accelerate development of earlier-stage gene therapy programs with three additional programs entering clinical testing over the next year - - Current cash of approximately $100 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results